Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBXNASDAQ:OGINASDAQ:PMVPNASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx$12.91-1.7%$12.46$10.80▼$34.50$186.89MN/A149,120 shs29,163 shsOGIOrganigram$1.35+1.1%$1.12$0.85▼$2.08$180.68M1.35669,531 shs596,092 shsPMVPPMV Pharmaceuticals$0.90+0.0%$0.98$0.81▼$1.98$46.76M1.5234,118 shs683,927 shsTLSATiziana Life Sciences$1.39-2.8%$1.21$0.63▼$1.91$162.42M0.29476,901 shs310,072 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx+2.10%+0.46%+7.10%+4.21%-61.54%OGIOrganigram-2.55%-1.11%+15.09%+15.09%-26.65%PMVPPMV Pharmaceuticals-0.66%-3.31%-13.46%-37.06%-55.88%TLSATiziana Life Sciences-9.49%-4.67%+5.15%+45.92%+76.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINBXInhibrx1.9125 of 5 stars0.01.00.04.63.02.51.3OGIOrganigram1.0194 of 5 stars0.03.00.00.03.80.01.3PMVPPMV Pharmaceuticals2.7288 of 5 stars3.53.00.00.03.51.70.6TLSATiziana Life Sciences0.9989 of 5 stars0.05.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBXInhibrx 2.00HoldN/AN/AOGIOrganigram 3.00BuyN/AN/APMVPPMV Pharmaceuticals 3.00Buy$5.50511.04% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMVP, INBX, TLSA, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025INBXInhibrxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform3/20/2025PMVPPMV PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBXInhibrx$200K934.43N/AN/AN/A∞OGIOrganigram$194.09M0.93N/AN/A$1.83 per share0.74PMVPPMV PharmaceuticalsN/AN/AN/AN/A$4.41 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBXInhibrx-$154.96M$116.750.11N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%8/12/2025 (Estimated)PMVPPMV Pharmaceuticals-$68.96M-$1.18N/AN/AN/AN/A-24.20%-21.67%8/14/2025 (Estimated)TLSATiziana Life Sciences-$17.69MN/A0.00∞N/AN/AN/AN/AN/ALatest PMVP, INBX, TLSA, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx-$2.55-$2.80-$0.25-$2.80N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 million3/3/2025Q4 2024PMVPPMV Pharmaceuticals-$0.37-$0.45-$0.08-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBXInhibrxN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBXInhibrxN/A4.704.70OGIOrganigramN/A3.361.85PMVPPMV PharmaceuticalsN/A13.9813.98TLSATiziana Life SciencesN/A0.85N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBXInhibrx82.46%OGIOrganigram34.63%PMVPPMV Pharmaceuticals90.20%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipINBXInhibrx17.09%OGIOrganigram0.09%PMVPPMV Pharmaceuticals7.57%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBXInhibrx16614.48 million11.26 millionOptionableOGIOrganigram860133.84 million126.10 millionOptionablePMVPPMV Pharmaceuticals5051.95 million47.81 millionOptionableTLSATiziana Life Sciences8116.85 million63.43 millionOptionablePMVP, INBX, TLSA, and OGI HeadlinesRecent News About These CompaniesTiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?May 28 at 1:36 AM | marketbeat.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Here's What HappenedMay 27 at 1:37 AM | americanbankingnews.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's DiseaseMay 23, 2025 | globenewswire.comJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comTiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsMay 15, 2025 | proactiveinvestors.comTiziana Life Sciences reports purchase of shares by chairmanMay 12, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by ChairmanMay 12, 2025 | globenewswire.comTiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumabMay 9, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal ForalumabMay 9, 2025 | globenewswire.comTiziana Life Sciences’ intranasal MS candidate shows promise in open-label studyMay 8, 2025 | pmlive.comTiziana shares surge 21% on promising multiple sclerosis dataMay 6, 2025 | proactiveinvestors.comTiziana reports encouraging results for nasal MS drug in early studyMay 6, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple SclerosisMay 6, 2025 | globenewswire.comWhy Tiziana Life Sciences Ltd (TLSA) is Surging in 2025April 30, 2025 | insidermonkey.comTiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of MassachusettsApril 23, 2025 | proactiveinvestors.comTiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis TrialApril 23, 2025 | globenewswire.comTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3, 2025 | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2, 2025 | globenewswire.comTiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSMarch 25, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMVP, INBX, TLSA, and OGI Company DescriptionsInhibrx NASDAQ:INBX$12.91 -0.22 (-1.68%) Closing price 04:00 PM EasternExtended Trading$12.90 -0.01 (-0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Organigram NASDAQ:OGI$1.35 +0.02 (+1.12%) Closing price 04:00 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.PMV Pharmaceuticals NASDAQ:PMVP$0.90 +0.00 (+0.01%) Closing price 04:00 PM EasternExtended Trading$0.90 0.00 (-0.01%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Tiziana Life Sciences NASDAQ:TLSA$1.39 -0.04 (-2.80%) Closing price 03:59 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
